Monthly Archives: July, 2010
ACADIA Pharmaceuticals Announces Initiation of New Phase III
ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial with Pimavanserin for Parkinson’s Disease Psychosis ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate [...]
VVUS rejection no supprise
VVUS with a FDA rejection, if you was watching Adams Feuerstein’s live blog you will already know why this drug failed. There was not enough long term data to support the long term side effects of its new drug qnexa. The advisory committee to the Food and Drug Administration voted 10 to 6 that the [...]
VVUS going to open after hours 6.00pm
Just of the wire VVUS is going to trade @ 6.00pm. http://www.nasdaqtrader.com/Trader.aspx?id=Tradehalts
FDA Reject VVUS new drug Qnexa
Vivus Inc’s VVUS :NASDAQ food and Drug Administration panel has voted 10-6 against Vivus Inc.’s Qnexa citing the experimental obesity treatment’s negative side effects. Federal health advisers say the negative effects on concentration and memory outweigh its ability to help patients lose weight. The vote deals a major setback to the Mountainview, Calif., drugmaker which [...]
Vivus fat pill works safety a concern FDA staff
Vivus Inc’s VVUS :NASDAQ experimental obesity pill appears to help people shed pounds, but concerns remain about its safety, U.S. Food and Drug Administration staff said in documents made public on Tuesday ahead of a public meeting on the drug later this week. The biotechnology company wants to market its once-a-day pill, Qnexa, for use [...]
Biodel Announces Research Grants by Juvenile Diabetes Research Foundation
Biodel Announces Research Grants by Juvenile Diabetes Research Foundation to Evaluate Use of VIAject(R) in Treatment of Diabetes July 12, 2010 – Biodel Inc. (Nasdaq: BIOD) announced today the award of two research grants by the Juvenile Diabetes Research Foundation (www.jdrf.org) to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use [...]